Rebekah Elisabeth Doyle, PA

Rebekah Doyle practices at Parks Dermatology Center -ormond Beach in Ormond Beach, Florida.

Rebekah Doyle's NPI, 1598879017, was assigned on August 19, 2006. Rebekah Doyle holds Florida license PA9103816.

Rebekah Doyle's primary practice is Parks Dermatology Center -ormond Beach, at 400 Lakebridge Plaza Dr, Ormond Beach, FL 32174-5157. The practice phone is (386) 677-9044.

Rebekah Doyle's primary practice is Parks Dermatology Center -ormond Beach in Ormond Beach, Florida. Rebekah Doyle is also affiliated with AdventHealth Palm Coast. The medical group on file is Parks Dermatology Center. Dmand AI also links Rebekah Doyle to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Rebekah Doyle practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Rebekah Doyle's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Rebekah Doyle is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Rebekah Doyle is licensed in Florida.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, corns and calluses, facial skin infection and hives among the conditions Rebekah Doyle treats.

CMS data shows 11,493 Medicare services from Rebekah Doyle across 19 procedure codes in 2024, for 1,441 Medicare patients. Medicare paid $343,862 for them. Every service was in an office.

CMS counts 1,441 Medicare patients who saw Rebekah Doyle in 2024. The largest group is 65 to 74, with 644 patients. 75% of them have high cholesterol, and 73% have high blood pressure. Their average risk score is 0.96, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Rebekah Doyle's median patient age at 72, with 56% women.

In 2024, Rebekah Doyle wrote 2,011 Medicare Part D claims for 980 patients. 96% of them were for generic drugs. CMS names the drug for 1,935 of them, across 26 drugs with 11 or more claims each, at $102,218 in total drug cost. In 2023, CMS named 1,655 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Rebekah Doyle for performance year 2024, reported as part of a group. Rebekah Doyle accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 259 general payments to Rebekah Doyle from 23 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 97% of the total. Abbvie Inc. paid the most, $1,274.

Rebekah Doyle is a member of AAPA.